Neurocrine Biosciences, Inc.

NBIX

US64125C1099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2026 am IST			5-day change	1st Jan Change
158.42 ^USD	-0.40%		+4.05%	+11.70%

13/05	Neurocrine Biosciences, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 11:20 AM
07/05	Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $155 From $150, Maintains Hold Rating	MT

Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover

Published on 04/07/2026 at 10:46 pm IST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Neurocrine Biosciences, Inc.

13/05	Neurocrine Biosciences, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 11:20 AM
07/05	Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $155 From $150, Maintains Hold Rating	MT
06/05	Neurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says	MT
06/05	Wedbush Adjusts Price Target on Neurocrine Biosciences to $176 From $166, Maintains Outperform Rating	MT
06/05	Oppenheimer Adjusts Price Target on Neurocrine Biosciences to $230 From $220, Maintains Outperform Rating	MT
06/05	Morgan Stanley Raises Price Target on Neurocrine Biosciences to $191 From $185, Keeps Equalweight Rating	MT
06/05	Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction After Initiating CRENESSITY for the Treatment of Classic Congenital Adrenal Hyperplasia	CI
06/05	Neurocrine Biosciences, Inc., Q1 2026 Earnings Call, May 05, 2026
06/05	Neurocrine Biosciences Q1 Adjusted Earnings, Revenue Rise	MT
06/05	Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q1 Revenue $814.5M, vs. FactSet Est of $768.3M	MT
06/05	Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q1 Adjusted EPS $1.94 per Share, vs. FactSet Est of $1.73	MT
06/05	Neurocrine Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04/05	Neurocrine Biosciences Initiates Phase 1 Study of Obesity Therapy	MT
04/05	Neurocrine Biosciences announces new survey results showing significant burden of tardive dyskinesia on employment	RE
04/05	Neurocrine Biosciences, Inc. Announces New Survey Results Showing Significant Burden Of Tardive Dyskinesia On Employment	CI

Chart Neurocrine Biosciences, Inc.

Duration

Period

NBIX: Dynamic Chart

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntingtonâ€™s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Employees

2,000

Sector

Pharmaceuticals

More about the company